Adverse event reporting: NLP’s new niche?

Getting critical treatments approved and delivered to market is no easy feat. Currently, only 15% of drugs successfully make it from clinical trials to U.S. FDA approval—with nearly 75% of failures attributed to safety and efficacy concerns. Once drugs do […]

Read More

Strategies for effective patient services programs

Patient adherence to therapy continues to be a challenge for pharmaceutical manufacturers. New complex patient journeys and multi-channel brand distribution models make it increasingly difficult to address patient barriers to adherence. Manufacturers continue to spend millions of dollars on patient […]

Read More

Spinning up the pharma traceability wheel

There are centrifugal and centripetal forces carrying along the drive toward pharma traceability today: forces that bring the pharma supply chain into a more united and cohesive effort (centripetal); forces that are sending supply chain participants in different directions (centrifugal). […]

Read More

Speed-date with the DSCSA pilot project sponsors

Bells didn’t exactly ring out when the organizations conducting pilot projects addressing the Drug Supply Chain Security Act (DSCSA) filed their reports with FDA. That agency had picked 20 companies or groups to evaluate a range of technical and business […]

Read More